Special Edition: Lp(a) & CV Risk
About this episode
Dr. Neil Skolnik discusses the significance of Lipoprotein(a) as a cardiovascular risk factor with Dr. Michael Wilkinson.
Over two decades ago, Lipoprotein(a)—or Lp(a)—was recognized as an emerging risk factor for cardiovascular disease. In this special edition of DOC Updates , Dr. Neil Skolnik explores our growing understanding of this cholesterol-carrying lipoprotein. This special episode is sponsored with support from Lilly . Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts , Amazon Music , Spotify , or your preferred podcast platform. EPISODE NOTES Special Edition: Special Edition: Lp(a) & CV Risk In this special edition of DOC Updates , Neil Skolnik speaks with Dr. Michael Wilkinson, who goes over the history of Lp(a), the current guidelines, and the importance of screening. This special episode is sponsored with support from Lilly . Presented by: - Neil Skolnik , MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health - Michael Wilkinson , MD, Associate Professor of Medicine at University of California San Diego Health, and Director of the advanced lipid treatment program at UC San…
People in this episode
Host: Neil Skolnik
Guest: Michael Wilkinson
Topics covered
- Lipoprotein(a)
- cardiovascular disease
- screening
- cholesterol
- medical guidelines
Keywords
- Lp(a)
- cardiovascular risk
- cholesterol
- screening guidelines
- lipid treatment
Sponsors
Lilly
Mentioned in this episode
Organizations: American Heart Association, National Lipid Association, American Journal of Preventive Cardiology
Books & works: Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects
Places: University of California San Diego Health, Sidney Kimmel Medical College, Thomas Jefferson University, Abington Jefferson Health
More episodes of DOC Updates
- Special Edition: Hypertension Part 2—Advanced Hypertension Management: Uncontrolled and Resistant Hypertension and the Importance of Aldosterone
- Special Edition: Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Special Edition: Evidence-Based Strategies for Weight Loss and Long-Term Weight Maintenance
- Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D
- Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more!
- Impact of Finerenone on Albuminuria in T1D, National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs, and more!
Explore listener stats, chart rankings, contacts and more on the DOC Updates podcast page.